Company intelligence / Profile preview
Blaze Bioscience
Seattle, Washington, United Statesblazebioscience.com ↗
- Ownership
- Private
- Employees
- ~17
- Development stage
- Other
01
Overview
Completed enrollment for pivotal Phase 2/3 trial of tozuleristide and the Canvas Imaging System in pediatric central nervous system tumors. BLZ-100 (tozuleristide) received Fast Track Designation from FDA for pediatric central nervous system tumors. Clinical proof-of-concept has been demonstrated in brain, breast, and skin cancer.
- Therapeutic areas
- Oncology
- Modalities
- Fluorescence-guided cancer surgery productspeptide-based imaging agents
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Fred Hutchinson Cancer Research CenterPacific Pediatric Neuro-Oncology Consortium (PNOC)unidentified pharmaceutical company for immuno-oncology pipeline
Beyond the preview
Go deeper on Blaze Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Blaze Bioscience.